tiprankstipranks
ESSA Pharma Inc (EPIX)
NASDAQ:EPIX
US Market
Holding EPIX?
Track your performance easily

ESSA Pharma (EPIX) Income Statement

271 Followers

ESSA Pharma Income Statement

Last quarter (Q3 2024), ESSA Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, ESSA Pharma's net income was $-7.23M. See ESSA Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Sep 23Sep 22Sep 21Sep 20Sep 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 33.88M$ 32.14M$ 36.96M$ 37.17M$ 24.14M$ 12.75M
Operating Income
$ -33.87M$ -32.13M$ -36.95M$ -37.12M$ -22.90M$ -11.55M
Net Non Operating Interest Income Expense
$ 6.21M$ 5.55M$ -1.72M$ 235.00K-$ 26.25K
Other Income Expense
$ 1.63M$ 6.53K$ 22.04K$ -107.02K$ 110.86K$ -1.16K
Pretax Income
$ -27.67M$ -26.58M$ -35.22M$ -36.84M$ -23.73M$ -12.72M
Tax Provision
-$ 1.60K$ -111.82K$ -34.35K$ -288.65K$ 37.92K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -27.67M$ -26.57M$ -35.10M$ -36.81M$ -23.45M$ -11.55M
Basic EPS
$ -0.62$ -0.60$ -0.80$ -0.96$ -1.04$ -1.24
Diluted EPS
$ -0.62$ -0.60$ -0.80$ -0.96$ -1.04$ -1.24
Basic Average Shares
$ 176.83M$ 44.09M$ 44.04M$ 38.48M$ 22.44M$ 8.43M
Diluted Average Shares
$ 176.83M$ 44.09M$ 44.04M$ 38.48M$ 22.44M$ 8.43M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 33.88M$ 32.14M$ 36.96M$ 37.17M$ 24.14M$ 12.75M
Net Income From Continuing And Discontinued Operation
$ -27.67M$ -26.58M$ -35.10M$ -36.81M$ -23.45M$ -12.76M
Normalized Income
$ -17.40M$ -21.00M-$ -36.87M--
Interest Expense
------
EBIT
$ -27.67M$ -26.58M$ -35.20M$ -36.82M$ -23.12M$ -10.81M
EBITDA
$ -27.34M$ -27.13M$ -34.94M$ -36.71M$ -23.01M$ -10.81M
Currency in USD

ESSA Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis